North America Cancer Diagnostics Market Size & Outlook
North America cancer diagnostics market, 2018-2030 (US$M)
Related Markets
North America cancer diagnostics market highlights
- The North America cancer diagnostics market generated a revenue of USD 45,120.9 million in 2024.
- The market is expected to grow at a CAGR of 6.3% from 2025 to 2030.
- In terms of segment, public insurance was the largest revenue generating coverage in 2024.
- Public insurance is the most lucrative coverage segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2025 to 2030.
North America data book summary
| Market revenue in 2024 | USD 45,120.9 million |
| Market revenue in 2030 | USD 64,538.1 million |
| Growth rate | 6.3% (CAGR from 2025 to 2030) |
| Largest segment | Public insurance |
| Fastest growing segment | Public insurance |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Public insurance, Private |
| Key market players worldwide | Abbott Laboratories, Roche Holding AG, GE HealthCare Technologies Inc Common Stock, Qiagen NV, Becton Dickinson & Co, Koninklijke Philips NV, Siemens Healthineers AG ADR, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc |
Other key industry trends
- In terms of revenue, North America region accounted for 41.2% of the global cancer diagnostics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 31,420.2 million by 2030.
Public insurance was the largest segment with a revenue share of 63.35% in 2024. Horizon Databook has segmented the North America cancer diagnostics market based on public insurance, private covering the revenue growth of each sub-segment from 2018 to 2030.
North America dominated the global cancer diagnostics market in 2023, primarily influenced by key product launches. For instance, in July 2022, Nanostics, Inc. announced the launch of a clinical investigation to identify the most effective indicators of bladder cancer for early detection.
It studied a minimally invasive liquid biopsy test to diagnose bladder cancer using the Nanostics ClarityDX diagnostic platform. Similarly, in February 2018, Genomic Health, Inc. launched a liquid biopsy test, Oncotype DX AR-V7 Nucleus Detect.
Developed in collaboration with Epic Sciences, this liquid biopsy test enables accurate detection of androgen receptor protein that circulates tumor cells. Thus, a rise in the launch of technologically advanced products is expected to fuel the usage of cancer diagnostic tests.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Diagnostics Market Scope
Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America cancer diagnostics market size, by country, 2018-2030 (US$M)
North America Cancer Diagnostics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
